Get the Stockscreener App
6.18
7.85%
0.45
After Hours:
6.18
Champions Oncology Inc stock is traded at $6.18, with a volume of 6,065.
It is up +7.85% in the last 24 hours and up +1.31% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$5.73
Open:
$5.8599
24h Volume:
6,065
Relative Volume:
0.81
Market Cap:
$85.82M
Revenue:
$57.94M
Net Income/Loss:
$-2.34M
P/E Ratio:
-37.09
EPS:
-0.1666
Net Cash Flow:
$3.82M
1W Performance:
+2.49%
1M Performance:
+1.31%
6M Performance:
-6.08%
1Y Performance:
-23.13%
1-Day Range:
$5.74
$6.18
1-Week Range:
$5.6783
$6.18
52-Week Range:
$5.50
$9.6299
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
6.18 | 79.57M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Aug Decliners: How does Champions Oncology Inc compare to its peersMarket Activity Report & Growth Focused Investment Plans - baoquankhu1.vn
Aug Catalysts: What is Champions Oncology Incs debt to equity ratio2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Chipmakers Recap: Should I average down on ACMR stockWeekly Profit Recap & Long-Term Growth Portfolio Plans - baoquankhu1.vn
CSBR Should I Buy - Intellectia AI
Champions Oncology to present eight studies at AACR meeting By Investing.com - Investing.com Australia
Champions Oncology to present eight studies at AACR meeting - Investing.com
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 - ACCESS Newswire
Eight cancer studies from Champions Oncology focus on drug response, resistance - Stock Titan
Bond Watch: Can Champions Oncology Inc weather a recessionWeekly Trading Summary & Verified Technical Signals - baoquankhu1.vn
Patient Derived Xenograft (PDX) Models Market is estimated - openPR.com
How does Champions Oncology Inc compare to its peers2026 Biggest Moves & Growth-Oriented Investment Plans - baoquankhu1.vn
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
CSBR Forecast, Price Target & Analyst Ratings | CHAMPIONS ONCOLOGY INC (NASDAQ:CSBR) - ChartMill
Understanding Momentum Shifts in (CSBR) - Stock Traders Daily
Performance Recap: What is Champions Oncology Incs debt to equity ratioMarket Risk Summary & Community Trade Idea Sharing - baoquankhu1.vn
CSBR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Champions Oncology, Inc.Common Stock (NQ: CSBR - The Chronicle-Journal
Market Review: How correlated is Champions Oncology Inc to the S P5002026 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform - STT Info
CSBR PE Ratio & Valuation, Is CSBR Overvalued - Intellectia AI
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago - NTB Kommunikasjon
Datavault AI and Coppercore Inc. Announce Tokenization of High-Grade Copper Resources into Coppercoin(TM) - STT Info
Champions Oncology appoints Brian Alexander to board By Investing.com - Investing.com Australia
Risk Off: How does Champions Oncology Inc compare to its peersLayoff News & Technical Pattern Based Buy Signals - baoquankhu1.vn
Champions Oncology Adds Director to Advance Data-Driven Strategy - TipRanks
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy - irw-press.com
Champ appoints Dr. Brian Alexander to board after Dr. Philip Breitfeld resignation - TradingView
Brian Alexander joins Champions Oncology (NASDAQ: CSBR) board - Stock Titan
Stock Market Recap: Will Champions Oncology Inc benefit from geopolitical trends2026 Bull vs Bear & Safe Entry Momentum Tips - baoquankhu1.vn
Champions Oncology appoints Brian Alexander to board - Investing.com
Champions Oncology taps data-focused cancer doctor for board seat - Stock Titan
Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World - STT Info
Safe Staffing Requires New Models of Care, Not Just More Clinicians, Says Global Taskforce - STT Info
Champions Oncology, Inc. Appoints Brian Alexander to Board of Directors - marketscreener.com
MAIA PE Ratio & Valuation, Is MAIA Overvalued - Intellectia AI
Targets Report: Is Vinci Partners Investments Ltd a good ESG investment2026 Reactions & Verified Trade Idea Suggestions - baoquankhu1.vn
New Highs: Is Champions Oncology Inc showing insider buying2026 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Valuation Update: Is Champions Oncology Inc stock trending bullishWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (CSBR) Movement - Stock Traders Daily
Champions Oncology outlines full year revenue growth and positive adjusted EBITDA targets amid early traction in data business - MSN
IPO Launch: Is FOXXW stock undervalued right nowTrade Risk Assessment & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Strengthening Preclinical Packages for FDA Radiopharmaceutical Approval - PharmTech.com
Nasdaq Moves: What is the Moat Score of Champions Oncology Inc2026 Price Action Summary & Verified Chart Pattern Signals - baoquankhu1.vn
Trading Action: How does Champions Oncology Inc score in quality rankingsEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Nasdaq Moves: How correlated is Champions Oncology Inc to the S P5002026 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
Guidance Update: Will Champions Oncology Inc benefit from geopolitical trends2026 Snapshot & Verified Entry Point Signals - baoquankhu1.vn
S P Trends: Is Champions Oncology Inc benefiting from innovation trendsMarket Risk Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Champions Oncology Inc (CSBR) Q3 2026 Earnings Call Highlights: Record Services Revenue and ... By GuruFocus - Investing.com Canada
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2026 earnings call transcript - MSN
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution - NTB Kommunikasjon
Champions Oncology reports Q3 revenue of $16.6 million - Investing.com Nigeria
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):